

FOR IMMEDIATE RELEASE

## **MFG Wins Contract with Intervet To Develop Second Phase of Clinical Trial System**

**SOMERSET, New Jersey, September 24, 2003** – MFG Systems Corporation has been selected to develop the second phase of a Clinical Trial system that they had developed for Intervet Inc, the U.S. division of the world's second largest animal health company, Intervet International, a division of Akzo Nobel.

In the summer of 2001, Intervet contacted MFG Systems to provide an automated solution for entering and maintaining clinical trial information. Since each clinical trial is unique and captures different information, providing an automated solution for handling this information was a challenge. Since Intervet was already an Oracle shop, MFG Systems recommended a solution that included Oracle's 9i Application Server for deployment and Oracle's Portal development product for application development. Using this technology, MFG created a dynamic forms engine for defining each unique clinical trial. Security for the application was critical and needed to be assigned on a functional basis. MFG Systems took advantage of Oracle's Virtual Private Database (VPD) to enforce security function-by-function and to allow a user to see only the data that they had access to. Integrated analytical capabilities using Oracle's Discoverer for ad hoc query and analysis was also part of the solution.

"With this solution Intervet has found a highly functional and cost effective way to build and deploy a Clinical Trials system. The uniqueness of the application is the ability to dynamically generate screens for any type of Clinical Trial. Oracle Portal made this solution possible whereas other tools were just not capable of supporting the requirements." - Peter Brassington, Director of Emerging Technologies, MFG Systems Corporation

The first phase of the Intervet Clinical Trials application was very well received by the Clinical Trial managers. For the first time, these managers are able to standardize on the terminology and approach to creating the forms for a new trial. The challenge now is to move on to the next phase. Phase One was viewed as a proof-of-concept and prototype of the required functionality. The second phase includes a wider rollout of the application in the field, the ability to upload external data from Excel spreadsheets into the Clinical Trials system and the migration to version 2 of the Oracle 9i Application Server, which is a core competency for MFG Systems. MFG will also work with Intervet to ensure that the system is validated according to the Validation guidelines published by the Food & Drug Administration (FDA).

Due to MFG's ability to deliver key functionality quickly and within budget, MFG Systems was selected to implement and deliver the second phases of the Clinical Trials system.

###

### **About MFG**

MFG Systems combines the leadership and expertise relied upon by the Oracle community with a proven track record in business-critical enterprise IT environments to deliver business solutions, including database services, application development, support, software products and training. MFG's expertise lies in all areas of Oracle competency with specialists in various complementary technologies including Java, XML, Oracle 9ias, Business Intelligence, Portal and Perl for a wide variety of industries including pharmaceutical, chemical, manufacturing and financial. MFG also provides on-site and remote database Administration services through our dbGuardian™ service offering. In Addition, our AppsGuardian™ service provides on-site application support for our clients as well as remote application support services.

For more information, please contact:



**Jeff Jafolla**  
**Director of Sales**  
**MFG Systems Corporation**  
**100 Davidson Avenue**  
**Somerset, N.J. 08873**  
**Phone: (732)-560-0010 x201**  
**Fax: (732)-805-1989**  
**Email: [jjafolla@mfgsys.com](mailto:jjafolla@mfgsys.com)**

Copyright © 2003, MFG Systems Corporation. All rights reserved.